Array
(
[1632432204] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1632433173] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1632433261] => Array
(
[wpseo_permalink_structure_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
[wpseo_home_url_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632433274] => Array
(
[wpseo-reindex] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632433681] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1632435110] => Array
(
[w3_pgcache_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => w3_pgcache_cleanup
[args] => Array
(
)
[interval] => 3600
)
)
)
[1632447126] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1632450553] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1632453473] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1632464685] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632467177] => Array
(
[non_recur_subs_daily] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632467312] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632473371] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632474032] => Array
(
[publish_future_post] => Array
(
[a4dd3189df89dd7a24a5b085a8a35d59] => Array
(
[schedule] =>
[args] => Array
(
[0] => 604709
)
)
)
)
[1632478511] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632478552] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632479214] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632491074] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632491400] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[e1e0950109edc977b88817290daef933] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1632491400
)
)
)
)
[1632499624] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632502611] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1632750600] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[0a4d1b21dccb4c337185772725b8e60d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1632750600
)
)
)
)
[1632896690] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
)
Etiquetas: 08/07/2010, 8 de julio de 2010, BOE, Boletín Oficial del Estado, Comercio exterior, Fabricación industrial, Fabricantes, Fabricantes de principios activos, Importadores de medicamentos, Laboratorios farmacéuticos, medicamentos, Medicamentos en investigación, principios activos, Real Decreto, salud, Sanidad, Uso farmacéutico.
Etiquetas: 29 noviembre 2010, 29/11/2009, AEMPS, Agencia española de medicamentos y productos sanitarios, Agencia Europea de Medicamentos, Buenas prácticas de distribución, Documento, Fabricación, Fabricación de principios activos, importación, Madrid, medicamentos, Medicamentos en investigación, Normas de correcta fabricación, Preguntas y respuestas, Real Decreto, Registro Unificado de Empresas fabricantes de Sustancias Activas, Representantes locales, salud, Sanidad, Titular de autorización de comercialización.
Etiquetas: 10 julio 2007, 10/07/2007, Acceso a medicamentos en condiciones diferentes a las autorizadas en España, Acceso a medicamentos en investigación, Actuaciones de la Agencia Española de Medicamentos y Productos Sanitarios, Agencia Europea de Medicamentos, Ámbito de aplicación, Boletín Oficial del Estado, Comité de Medicamentos de Uso Humano, Definiciones, Disponibilidad de medicamentos en situaciones especiales, Ensayo clínico, Ley de Garantías y Uso Racional de Medicamentos y Productos Sanitarios, Madrid, medicamentos, Medicamentos en investigación, Medicamentos en situaciones especiales, Medicamentos no autorizados a pacientes, Medicamentos sin autorización en España, Obligaciones del facultativo responsable del tratamiento y actuaciones del Centro sanitario, Obligaciones del laboratorio farmacéutico importador, proyecto, Real Decreto, salud, Sanidad, Situaciones especiales, Solicitud para el acceso a medicamentos en investigación mediante un protocolo autorizado, Solicitud para el acceso individualizado a medicamentos en investigación, Uso compasivo de medicamentos en investigación.
.gif)